Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects

Yang, Yu-an; Dukhanina, Oksana; Tang, Binwu; Mamura, Mizuko; Letterio, John J.; MacGregor, Jennifer; Patel, Sejal C.; Khozin, Shahram; Liu, Zi-yao; Green, Jeffrey; Anver, Miriam R.; Merlino, Glenn; Wakefield, Lalage M.

doi:10.1172/jci200215333

Cited by 405TGF-β signaling in diseasesMechanisms of cancer metastasisCancer Cells and Metastasis

Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects

Open access

Yang, Yu-an, Dukhanina, Oksana, Tang, Binwu, Mamura, Mizuko, Letterio, John J., MacGregor, Jennifer, Patel, Sejal C., Khozin, Shahram +5 more·2002·Journal of Clinical Investigation

DOI 10.1172/jci200215333PMC PMC151015

Open this paper in CoChat — free account Open PDF

Abstract

TGF-βs play diverse and complex roles in many biological processes. In tumorigenesis, they can function either as tumor suppressors or as pro-oncogenic factors, depending on the stage of the disease. We have developed transgenic mice expressing a TGF-β antagonist of the soluble type II TGF-β receptor:Fc fusion protein class, under the regulation of the mammary-selective MMTV-LTR promoter/enhancer. Biologically significant levels of antagonist were detectable in the serum and most tissues of this mouse line. The mice were resistant to the development of metastases at multiple organ sites when compared with wild-type controls, both in a tail vein metastasis assay using isogenic melanoma cells and in crosses with the MMTV-neu transgenic mouse model of metastatic breast cancer. Importantly, metastasis from endogenous mammary tumors was suppressed without any enhancement of primary tumorigenesis. Furthermore, aged transgenic mice did not exhibit the severe pathology characteristic of TGF-β null mice, despite lifetime exposure to the antagonist. The data suggest that in vivo the antagonist may selectively neutralize the undesirable TGF-β associated with metastasis, while sparing the regulatory roles of TGF-βs in normal tissues. Thus this soluble TGF-β antagonist has potential for long-term clinical use in the prevention of metastasis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci200215333

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Fc-TβRII trap was the basis for the development of a bi-specific trap that combines TGF-β binding by the TβRII ectodomains with a human PD-L1-blocking IgG1.
“The Fc-TβRII trap was also the basis for the development of a bi-specific trap that combines TGF-β binding by the TβRII ectodomains with a human PD-L1-blocking IgG1308,309,312.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [308]
Bifunctional fusion proteins that bind and block both TGF-β and CTLA-4 or PD-L1 have been generated, biochemically linking checkpoint inhibition with TGF-β blockade.
“Bifunctional fusion proteins that bind and block both TGF-β and CTLA-4 or PD-L1 have been generated, thus biochemically linking immune checkpoint inhibition with blocking TGF-β signaling308,309,365.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [308]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Manipulating the mouse embryo: A laboratory manual
Hogan, B., Costantini, F. D., & Lacy, E. (1986) · Cited by 4,467 · see citing works
Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease
Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992) · Nature · doi:10.1038/359693a0 · Cited by 2,985 · see citing works
TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders
Massagué, J., Blain, S. W., & Lo, R. S. (2000) · Cell · doi:10.1016/s0092-8674(00)00121-5 · Cited by 2,386 · see citing works
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275 · see citing works
Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death.
Kulkarni, A. B., Huh, C. G., Becker, D., Geiser, A., Lyght, M., Flanders, K. C., Roberts, A. B., Sporn, M. B., Ward, J. M., & Karlsson, S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.770 · Cited by 1,967 · see citing works
Peptide Growth Factors and Their Receptors
Arai, K., Battey, J. F., Sporn, M. B., & Roberts, A. B. (1991) · Medical Entomology and Zoology · Cited by 1,225 · see citing works
Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.
Guy, C. T., Webster, M. A., Schaller, M. D., Parsons, T. J., Cardiff, R. D., & Muller, W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10578 · Cited by 1,193 · see citing works
Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1
Border, W. A., Okuda, S., Languino, L. R., Sporn, M. B., & Ruoslahti, E. I. (1990) · Nature · doi:10.1038/346371a0 · Cited by 984 · see citing works
Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease
Border, W. A., Noble, N. A., Yamamoto, T., Harper, J. R., Yamaguchi, Y., Pierschbacher, M. D., & Ruoslahti, E. I. (1992) · Nature · doi:10.1038/360361a0 · Cited by 972 · see citing works
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
Wang, T. C., Cardiff, R. D., Zukerberg, L. R., Lees, E. M., Arnold, A., & Schmidt, E. V. (1994) · Nature · doi:10.1038/369669a0 · Cited by 964 · see citing works
Abrogation of TGFβ Signaling in T Cells Leads to Spontaneous T Cell Differentiation and Autoimmune Disease
Gorelik, L., & Flavell, R. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80170-3 · Cited by 959 · see citing works
The Transforming Growth Factor-βs
Roberts, A. B., & Sporn, M. B. (1991) · Springer eBooks · doi:10.1007/978-1-4612-3210-0_8 · Cited by 869 · see citing works
Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells
Gorelik, L., & Flavell, R. A. (2001) · Nature Medicine · doi:10.1038/nm1001-1118 · Cited by 770 · see citing works
TGF- and fibrosis
Branton, M., & Kopp, J. (1999) · Microbes and Infection · doi:10.1016/s1286-4579(99)00250-6 · Cited by 574 · see citing works
Distribution and modulation of the cellular receptor for transforming growth factor-beta.
Wakefield, L. M., Smith, D. M., Masui, T., Harris, C. C., & Sporn, M. B. (1987) · The Journal of Cell Biology · doi:10.1083/jcb.105.2.965 · Cited by 535 · see citing works
Self-citation
Role of Transforming Growth Factor-beta Signaling in Cancer
de Caestecker, M. P. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.17.1388 · Cited by 521 · see citing works
Latent transforming growth factor-β: Structural features and mechanisms of activation
Munger, J. S., Harpel, J. G., Gleizes, P., Mazzieri, R., Nunes, I., & Rifkin, D. B. (1997) · Kidney International · doi:10.1038/ki.1997.188 · Cited by 513 · see citing works
Immunodetection and quantitation of the two forms of transforming growth factor‐beta (TGF‐β1 and TGF‐β2) secreted by cells in culture
Danielpour, D., Dart, L. L., Flanders, K. C., Roberts, A. B., & Sporn, M. B. (1989) · Journal of Cellular Physiology · doi:10.1002/jcp.1041380112 · Cited by 441 · see citing works
Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
Arteaga, C. L., Hurd, S. D., Winnier, A. R., Johnson, M. D., Fendly, B. M., & Forbes, J. T. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116871 · Cited by 359 · see citing works
The role for transforming growth factor-beta (TGF-beta) in human cancer.
Gold, L. I. (1999) · PubMed · Cited by 322 · see citing works
Transforming growth factor-β1 is a new form of tumor suppressor with true haploid insufficiency
Tang, B., Böttinger, E. P., Jakowlew, S. B., Bagnall, K. M., Mariano, J. M., Anver, M. R., Letterio, J. J., & Wakefield, L. M. (1998) · Nature Medicine · doi:10.1038/nm0798-802 · Cited by 315 · see citing works
Self-citation
Disruption of T Cell Homeostasis in Mice Expressing a T Cell–Specific Dominant Negative Transforming Growth Factor β II Receptor
Lucas, P. J., Kim, S., Melby, S. J., & Gress, R. E. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.7.1187 · Cited by 244 · see citing works
Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression.
Letterio, J. J., Geiser, A. G., Kulkarni, A. B., Dang, H., Kong, L., Nakabayashi, T., Mackall, C. L., GRESS, R. E., & Roberts, A. B. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119017 · Cited by 232 · see citing works
Self-citation
Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis.
Engle, S. J., Hoying, J. B., Boivin, G. P., Ormsby, I., Gartside, P. S., & Doetschman, T. C. (1999) · PubMed · Cited by 216 · see citing works
Pathobiology of the aging mouse
Möhr, U., Dungworth, D. L., & Capen, C. C. (1996) · Medical Entomology and Zoology · Cited by 214 · see citing works
Critical Steps in Hematogenous Metastasis
Chambers, A. F., Naumov, G. N., Varghese, H. J., Nadkarni, K. V., MacDonald, I. C., & Groom, A. C. (2001) · Surgical Oncology Clinics of North America · doi:10.1016/s1055-3207(18)30063-2 · Cited by 210 · see citing works
Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma.
Dalal, B. I., Keown, P. A., & Greenberg, A. H. (1993) · PubMed Central · Cited by 208 · see citing works
Elevated Plasma Transforming Growth Factor-β1 Levels in Breast Cancer Patients Decrease After Surgical Removal of the Tumor
Kong, F., Anscher, M. S., Murase, T., Abbott, B. D., Iglehart, J. D., & Jirtle, R. L. (1995) · Annals of Surgery · doi:10.1097/00000658-199508000-00007 · Cited by 201 · see citing works
Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene.
Böttinger, E. P., Jakubczak, J. L., Haines, D. C., Bagnall, K. M., & Wakefield, L. M. (1997) · PubMed · Cited by 196 · see citing works
Self-citation
Critical steps in hematogenous metastasis: an overview.
Chambers, A. F., Naumov, G. N., Varghese, H. J., Nadkarni, K. V., MacDonald, I. C., & Groom, A. C. (2001) · PubMed · Cited by 191 · see citing works
Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters
Wang, Q., Wang, Y., Hyde, D. M., Gotwals, P. J., Koteliansky, V., Ryan, S. T., & Giri, S. N. (1999) · Thorax · doi:10.1136/thx.54.9.805 · Cited by 186 · see citing works
SLE-like autoantibodies and Sjögren's syndrome-like lymphoproliferation in TGF-β knockout mice
Dang, H., Geiser, A. G., Letterio, J. J., Nakabayashi, T., Kong, L., Fernandes, G., & Talal, N. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.6.3205 · Cited by 181 · see citing works
Self-citation
Overexpression of E2F‐1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo
Fueyo-Margareto, J., Gomez‐Manzano, C., Yung, W. K. A., Liu, T.-J., Alemany, R., McDonnell, T. J., Shi, X., Rao, J., Levin, V. A., & Kyritsis, A. P. (1998) · Nature Medicine · doi:10.1038/nm0698-685 · Cited by 175 · see citing works
A Soluble Transforming Growth Factor beta Receptor Expressed in Muscle Prevents Liver Fibrogenesis and Dysfunction in Rats
Ueno, H., Sakamoto, T., Nakamura, T., Qi, Z., Astuchi, N., Takeshita, A., Shimizu, K., & Ohashi, H. (2000) · Human Gene Therapy · doi:10.1089/10430340050016139 · Cited by 135 · see citing works
Gene therapy by transforming growth factor-β receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis
Isaka, Y., Akagi, Y., Ando, Y., Tsujie, M., Sudo, T., Ohno, N., Border, W. A., Noble, N. A., Kaneda, Y., Hori, M., et al. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00275.x · Cited by 129 · see citing works
TGF-β in infections and infectious diseases
Reed, S. G. (1999) · Microbes and Infection · doi:10.1016/s1286-4579(99)00252-x · Cited by 127 · see citing works
Expression of a dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development
Amendt, C., Schirmacher, P., Weber, H., & Blessing, M. (1998) · Oncogene · doi:10.1038/sj.onc.1202161 · Cited by 119 · see citing works
TGF-β and cancer
Reiß, M. (1999) · Microbes and Infection · doi:10.1016/s1286-4579(99)00251-8 · Cited by 118 · see citing works
Recombinant soluble transforming growth factor β type II receptor ameliorates radiation enteropathy in mice
Zheng, H., Wang, J., Koteliansky, V., Gotwals, P. J., & Hauer‐Jensen, M. (2000) · Gastroenterology · doi:10.1053/gast.2000.19282 · Cited by 110 · see citing works
Transforming growth factor-β and breast cancer: Mammary gland development
Barcellos‐Hoff, M. H., & Ewan, K. (2000) · Breast Cancer Research · doi:10.1186/bcr40 · Cited by 80 · see citing works
Manipulation of TGF-β to control autoimmune and chronic inflammatory diseases
Chen, W., & Wahl, S. M. (1999) · Microbes and Infection · doi:10.1016/s1286-4579(99)00249-x · Cited by 72 · see citing works
Chimeric extracellular domain of type II transforming growth factor (TGF)‐β receptor fused to the Fc region of human immunoglobulin as a TGF‐β antagonist
Komesli, S., Vivien, D., & Dutartre, P. (1998) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1998.2540505.x · Cited by 64 · see citing works
Modulation of B16 Melanoma Growth and Metastasis by Anti-Transforming Growth Factor ?? Antibody and Interleukin-2
Wojtowicz‐Praga, S., Verma, U. M., Wakefield, L. M., López-Jamar, J. M. E., Hartmann, D., & Mazumder, A. (1996) · Journal of Immunotherapy · doi:10.1097/00002371-199605000-00001 · Cited by 60 · see citing works
Self-citation
Aberrant TGF-β Production and Regulation in Metastatic Malignancy
SCHWARZ, L. C., Wright, J. A., Gingras, M., Kondaiah, P., Danielpour, D., Pimentel, M., Sporn, M. B., & Greenberg, A. H. (1990) · Growth Factors · doi:10.3109/08977199009108274 · Cited by 58 · see citing works
Soluble cytokine receptors: novel immunotherapeutic agents
Fernandez-Botrán, R. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.3.497 · Cited by 56 · see citing works
Disassociation of Met-Mediated Biological Responses In Vivo: the Natural Hepatocyte Growth Factor/Scatter Factor Splice Variant NK2 Antagonizes Growth but Facilitates Metastasis
Otsuka, T., Jakubczak, J. L., Vieira, W. D., Bottaro, D. P., Breckenridge, D., LaRochelle, W. J., & Merlino, G. T. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.6.2055-2065.2000 · Cited by 56 · see citing works
Self-citation
TGF-β in the Cardiovascular System
Topper, J. N. (2000) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(00)00061-x · Cited by 48 · see citing works
Anti-(transforming growth factor ?) antibodies with predefined specificity inhibit metastasis of highly tumorigenic human xenotransplants in nu/nu mice
Hoefer, M., & Anderer, F. A. (1995) · Cancer Immunology Immunotherapy · doi:10.1007/bf01517218 · Cited by 37 · see citing works
Reduction in transforming growth factor-β type II receptor in mouse lung carcinogenesis
Jakowlew, S. B., Moody, T. W., You, L., & Mariano, J. M. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199805)22:1 · Cited by 24 · see citing works
Genetic and Immunologic Determinants of Age-Related and Virus-Induced Cardiopathy
Price, P., & Papadimitriou, J. C. (1996) · UWA Profiles and Research Repository (University of Western Australia) · Cited by 3 · see citing works

Flagged first, then by citations

Sorted by citations

A multigenic program mediating breast cancer metastasis to bone
Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Käkönen, S.-M., Cordon‐Cardo, C., Guise, T. A., & Massagué, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00132-6 · Cited by 2,562 · see citing works
Stromal fibroblasts in cancer initiation and progression
Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004) · Nature · doi:10.1038/nature03096 · Cited by 2,291 · see citing works
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1208 · Cited by 1,600 · see citing works
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466 · see citing works
TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia
Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E., Dumont, N., Shappell, S., Washington, M. K., Neilson, E. G., & Moses, H. L. (2004) · Science · doi:10.1126/science.1090922 · Cited by 1,401 · see citing works
Targeting metastasis
Steeg, P. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.25 · Cited by 1,363 · see citing works
TGFβ: the molecular Jekyll and Hyde of cancer
Bierie, B., & Moses, H. L. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1926 · Cited by 1,262 · see citing works
Role of tissue stroma in cancer cell invasion
De Wever, O., & Mareel, M. (2003) · The Journal of Pathology · doi:10.1002/path.1398 · Cited by 1,042 · see citing works
Targeting TGF-β Signaling in Cancer
Colak, S., & ten Dijke, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.008 · Cited by 1,003 · see citing works
New signals from the invasive front
Christofori, G. (2006) · Nature · doi:10.1038/nature04872 · Cited by 989 · see citing works
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944 · see citing works
The polarization of immune cells in the tumour environment by TGFβ
Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., & Licona-Limón, P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2808 · Cited by 940 · see citing works
Roles of TGFβ in metastasis
Padua, D. M., & Massagué, J. (2008) · Cell Research · doi:10.1038/cr.2008.316 · Cited by 810 · see citing works
The two faces of transforming growth factor β in carcinogenesis
Roberts, A. B., & Wakefield, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633291100 · Cited by 747 · see citing works
Self-citation
Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets
Gressner, A. M., & Weiskirchen, R. (2006) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2006.tb00292.x · Cited by 718 · see citing works
Role of Transforming Growth Factor Beta in Human Cancer
Elliott, R. L., & Blobe, G. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.047 · Cited by 705 · see citing works
Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis
Grünert, S., Jechlinger, M., & Beug, H. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1175 · Cited by 677 · see citing works
Targeting tumor‐associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake
Loeffler, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26532 · Cited by 633 · see citing works
Smad3 as a mediator of the fibrotic response
Flanders, K. C. (2004) · International Journal of Experimental Pathology · doi:10.1111/j.0959-9673.2004.00377.x · Cited by 610 · see citing works
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
Lahn, M. M. F., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A., Desaiah, D., Guba, S. C., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s86621 · Cited by 558 · see citing works
Development of TGF-β signalling inhibitors for cancer therapy
Yingling, J. M., Blanchard, K. L., & Sawyer, J. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1580 · Cited by 550 · see citing works
Transforming Growth Factor-β Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte–mediated Tumor Immunosurveillance
Terabe, M., Matsui, S., Park, J.-M., Mamura, M., Noben-Trauth, N., Donaldson, D. D., Chen, W., Wahl, S. M., Ledbetter, S. R., Pratt, B. M., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022227 · Cited by 533 · see citing works
Self-citation
Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer
Pardali, K., & Moustakas, A. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.06.004 · Cited by 532 · see citing works
Transforming growth factor-β in cancer and metastasis
Jakowlew, S. B. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9006-2 · Cited by 519 · see citing works
Regulation of EMT by TGFβ in cancer
Heldin, C., Vanlandewijck, M., & Moustakas, A. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.02.037 · Cited by 502 · see citing works
Platelet-Derived Transforming Growth Factor-β Down-Regulates NKG2D Thereby Inhibiting Natural Killer Cell Antitumor Reactivity
Kopp, H., Placke, T., & Salih, H. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2123 · Cited by 473 · see citing works
TGF-β-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing
Schiller, M., Javelaud, D., & Mauviel, A. (2004) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2003.12.006 · Cited by 468 · see citing works
Transforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy
Wrzesinski, S. H., Wan, Y. Y., & Flavell, R. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1157 · Cited by 452 · see citing works
Transforming growth factor β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis
Siegel, P. M., Shu, W., Cardiff, R. D., Muller, W. J., & Massagué, J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932636100 · Cited by 429 · see citing works
Pathobiology of transforming growth factor β in cancer, fibrosis and immunologic disease, and therapeutic considerations
Prud’homme, G. J. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700669 · Cited by 420 · see citing works
SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma CellsIn vitroandIn vivo
Uhl, M., Aulwurm, S., Wischhusen, J., Weiler, M., Jing, Y., Almirez, R. G., Mangadu, R., Liu, Y.-W., Platten, M., Herrlinger, U., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1013 · Cited by 414 · see citing works
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R. R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 411 · see citing works
TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression
Tang, B., Vu, M. A., Booker, T., Santner, S. J., Miller, F. R., Anver, M. R., & Wakefield, L. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18899 · Cited by 391 · see citing works
Self-citation
The dynamic roles of TGF‐β in cancer
Meulmeester, E., & ten Dijke, P. (2010) · The Journal of Pathology · doi:10.1002/path.2785 · Cited by 391 · see citing works
Autocrine PDGFR signaling promotes mammary cancer metastasis
Jechlinger, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24652 · Cited by 371 · see citing works
IL-13 Activates a Mechanism of Tissue Fibrosis That Is Completely TGF-β Independent
Kaviratne, M., Hesse, M., Leusink, M., Cheever, A. W., Davies, S. J., McKerrow, J. H., Wakefield, L. M., Letterio, J. J., & Wynn, T. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.4020 · Cited by 370 · see citing works
Self-citation
The Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer Metastasis
Neel, J.-C., Humbert, L., & Lebrun, J. J. (2012) · ISRN Molecular Biology · doi:10.5402/2012/381428 · Cited by 353 · see citing works
Smad3 is key to TGF-β-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis
ROBERTS, A., TIAN, F., Byfield, S. D., Stuelten, C. H., Ooshima, A., Saika, S., & Flanders, K. C. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.008 · Cited by 348 · see citing works
Complexities of TGF-β Targeted Cancer Therapy
Connolly, E. C., Freimuth, J., & Akhurst, R. J. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4564 · Cited by 344 · see citing works
TGF-β in Renal Injury and Disease
Böttinger, E. P. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.02.009 · Cited by 339 · see citing works
Mouse models of breast cancer metastasis
Fantozzi, A., & Christofori, G. (2006) · Breast Cancer Research · doi:10.1186/bcr1530 · Cited by 335 · see citing works
Transforming growth factor beta (TGF-β) and inflammation in cancer
Bierie, B., & Moses, H. L. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.008 · Cited by 331 · see citing works
Breast Cancer Metastasis
Marino, N., Woditschka, S., Reed, L. T., Nakayama, J., Mayer, M., Wetzel, M., & Steeg, P. S. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.06.012 · Cited by 309 · see citing works
TGF ‐β as a driver of fibrosis: physiological roles and therapeutic opportunities
Budi, E. H., Schaub, J. R., Decaris, M. L., Turner, S., & Derynck, R. (2021) · The Journal of Pathology · doi:10.1002/path.5680 · Cited by 300 · see citing works
Expression profiling of epithelial plasticity in tumor progression
Jechlinger, M., Grünert, S., Tamir, I. H., Janda, E., Lüdemann, S. K., Waerner, T., Seither, P., Weith, A., Beug, H., & Kraut, N. (2003) · Oncogene · doi:10.1038/sj.onc.1206887 · Cited by 295 · see citing works
Transforming growth factor β as a therapeutic target in systemic sclerosis
Varga, J., & Pasche, B. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.26 · Cited by 295 · see citing works
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
Tian, Y., Xie, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00951-x · Cited by 304 · see citing works
A Specific Inhibitor of TGF-β Receptor Kinase, SB-431542, as a Potent Antitumor Agent for Human Cancers
Halder, S. K., Beauchamp, R. D., & Datta, P. K. (2005) · Neoplasia · doi:10.1593/neo.04640 · Cited by 288 · see citing works
Inhibition of Integrin αvβ6, an Activator of Latent Transforming Growth Factor-β, Prevents Radiation-induced Lung Fibrosis
Puthawala, K., Hadjiangelis, N., Jacoby, S. C., Bayongan, E., Zhao, Z., Yang, Z., Devitt, M. L., Horan, G. S., Weinreb, P. H., Lukashev, M. E., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-806oc · Cited by 272 · see citing works
Therapeutic strategies against TGF‐β signaling pathway in hepatic fibrosis
Liu, X., Hu, H., & Yin, J. Q. (2005) · Liver International · doi:10.1111/j.1478-3231.2005.01192.x · Cited by 262 · see citing works
Effect of Conditional Knockout of the Type II TGF-β Receptor Gene in Mammary Epithelia on Mammary Gland Development and Polyomavirus Middle T Antigen Induced Tumor Formation and Metastasis
Forrester, E., Chytil, A., Bierie, B., Aakre, M. E., Gorska, A. E., Sharif‐Afshar, A., Muller, W. J., & Moses, H. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3272 · Cited by 248 · see citing works
Src Phosphorylates Tyr284 in TGF-β Type II Receptor and Regulates TGF-β Stimulation of p38 MAPK during Breast Cancer Cell Proliferation and Invasion
Galliher, A. J., & Schiemann, W. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3851 · Cited by 249 · see citing works
Targeting the TGFβ signaling network in human neoplasia
Dumont, N., & Arteaga, C. L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00135-1 · Cited by 243 · see citing works
Improving T Cell Therapy for Cancer
Leen, A. M., Rooney, C. M., & Foster, A. E. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141527 · Cited by 238 · see citing works
β3Integrin and Src facilitate transforming growth factor-β mediated induction of epithelial-mesenchymal transition in mammary epithelial cells
Galliher, A. J., & Schiemann, W. P. (2006) · Breast Cancer Research · doi:10.1186/bcr1524 · Cited by 236 · see citing works
An Anti–Transforming Growth Factor β Antibody Suppresses Metastasis via Cooperative Effects on Multiple Cell Compartments
Nam, J., Terabe, M., Mamura, M., Kang, M., Chae, H., Stuelten, C. H., Kohn, E. A., Tang, B., Sabzevari, H., Anver, M. R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0215 · Cited by 233 · see citing works
Self-citation
TGF-&beta; signaling in cancer metastasis
Xie, F., Ling, L., Van Dam, H., Zhou, F., & Zhang, L. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx123 · Cited by 231 · see citing works
TGF- Biology in Mammary Development and Breast CancerPreprint
Moses, H. L., & Barcellos‐Hoff, M. H. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003277 · Cited by 234 · see citing works
Cooperation of the ErbB2 receptor and transforming growth factor β in induction of migration and invasion in mammary epithelial cells
Seton-Rogers, S. E., Lu, Y., Hines, L. M., Koundinya, M., LaBaer, J., Muthuswamy, S. K., & Brugge, J. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308090100 · Cited by 224 · see citing works
Two Faces of TGF-Beta1 in Breast Cancer
Zarzynska, J. M. (2014) · Mediators of Inflammation · doi:10.1155/2014/141747 · Cited by 214 · see citing works
Targeting TGF-β signaling in cancer
Katz, L. H., Li, Y., Chen, J.-S., Muñoz, N. M., Majumdar, A., Chen, J., & Mishra, L. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.782287 · Cited by 212 · see citing works
Hypoxia and TGF-β Drive Breast Cancer Bone Metastases through Parallel Signaling Pathways in Tumor Cells and the Bone Microenvironment
Dunn, L. K., Mohammad, K. S., Fournier, P. G. J., McKenna, C. R., Davis, H. W., Niewolna, M., Peng, X. H., Chirgwin, J. M., & Guise, T. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006896 · Cited by 212 · see citing works
On-Target Anti-TGF-β Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges?
Teixeira, A. F., ten Dijke, P., & Zhu, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00605 · Cited by 210 · see citing works
Loss of transforming growth factor-β type II receptor promotes metastatic head-and-neck squamous cell carcinomaPreprint
Lu, S., Herrington, H. C., Reh, D. D., Weber, S. M., Bornstein, S., Wang, D., Li, A. G., Tang, C.-F., Siddiqui, Y., Nord, J., et al. (2006) · Genes & Development · doi:10.1101/gad.1413306 · Cited by 204 · see citing works
Hepatic stellate cells: Partners in crime for liver metastases?
Kang, N., Gores, G. J., & Shah, V. H. (2011) · Hepatology · doi:10.1002/hep.24384 · Cited by 201 · see citing works
Transforming Growth Factor-β in the Gastrointestinal and Hepatic Tumor Microenvironment
Achyut, B. R., & Yang, H. H. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.048 · Cited by 200 · see citing works
Stable Overexpression of Smad7 in Human Melanoma Cells Impairs Bone Metastasis
Javelaud, D., Mohammad, K. S., McKenna, C. R., Fournier, P. G. J., Luciani, F., Niewolna, M., André, J., Delmas, V., Larue, L., Guise, T. A., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3950 · Cited by 195 · see citing works
Molecular Pathways: Targeting the TGF-β Pathway for Cancer Therapy
Smith, A., Robin, T. P., & Ford, H. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3224 · Cited by 192 · see citing works
14-3-3ζ Cooperates with ErbB2 to Promote Ductal Carcinoma In Situ Progression to Invasive Breast Cancer by Inducing Epithelial-Mesenchymal Transition
Lü, J., Guo, H., Treekitkarnmongkol, W., Li, P., Zhang, J., Shi, B., Ling, C., Zhou, X., Chen, T., Chiao, P. J., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.08.010 · Cited by 193 · see citing works
Role of the tumor microenvironment in pancreatic cancer
Murakami, T., Hiroshima, Y., Matsuyama, R., Homma, Y., Hoffman, R. M., & Endo, I. (2019) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12225 · Cited by 188 · see citing works
ILEI: A cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells
Waerner, T., Alacakaptan, M., Tamir, I. H., Oberauer, R., Gal, A., Brabletz, T., Schreiber, M., Jechlinger, M., & Beug, H. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.020 · Cited by 189 · see citing works
TGF-beta Signaling in Cancer Treatment
Fabregat, I., Fernando, J., Mainez, J., & Sancho, P. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990591 · Cited by 185 · see citing works
Fibroblasts as novel therapeutic targets in chronic inflammation
Flavell, S. J., Hou, T. Z., Lax, S., Filer, A. D., Salmon, M., & Buckley, C. D. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707487 · Cited by 186 · see citing works
The role of endothelial-mesenchymal transition in development and pathological process
Lin, F., Wang, N., & Zhang, T. (2012) · IUBMB Life · doi:10.1002/iub.1059 · Cited by 177 · see citing works
Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines.
Tian, F., Byfield, S. D., Parks, W. T., Yoo, S. S., Felici, A., Tang, B., Piek, E., Wakefield, L. M., & Roberts, A. B. (2003) · PubMed · Cited by 177 · see citing works
Self-citation
Dual Role of Transforming Growth Factor β in Mammary Tumorigenesis and Metastatic Progression
Muraoka-Cook, R. S., Dumont, N., & Arteaga, C. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.937s.11.2 · Cited by 168 · see citing works
Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo
Adkins, H. B., Bianco, C., Schiffer, S. G., Rayhorn, P., Zafari, M. R., Cheung, A. E., Orozco, O. E., Olson, D. L., Luca, A. D., Chen, L. L., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17788 · Cited by 157 · see citing works
Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-β Type I Receptor Kinase In vivo
Ge, R., Rajeev, V., Ray, P., Lattime, E. C., Rittling, S. R., Medicherla, S., Protter, A., Murphy, A., Chakravarty, J., Dugar, S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0162 · Cited by 154 · see citing works
Radiation therapy causes loss of dermal lymphatic vessels and interferes with lymphatic function by TGF-β1-mediated tissue fibrosis
Avraham, T., Yan, A., Zampell, J. C., Daluvoy, S. V., Haimovitz‐Friedman, A., Cordeiro, A. P., & Mehrara, B. J. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00535.2009 · Cited by 154 · see citing works
Transforming Growth Factor β Receptor Type II Inactivation Promotes the Establishment and Progression of Colon Cancer
Biswas, S., Chytil, A. M., Washington, K., Romero–Gallo, J., Gorska, A. E., Wirth, P. S., Gautam, S., Moses, H. L., & Grady, W. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3255 · Cited by 153 · see citing works
Transforming Growth Factor-β
Mauviel, A. (2005) · Humana Press eBooks · doi:10.1385/1-59259-940-0:069 · Cited by 152 · see citing works
Cellular response to hypoxia involves signaling via Smad proteins
Zhang, H., Akman, H. O., Smith, E. L., Zhao, J., Murphy-Ullrich, J. E., & Batuman, O. (2003) · Blood · doi:10.1182/blood-2002-02-0629 · Cited by 152 · see citing works
Antibody-Mediated Blockade of Integrin αvβ6 Inhibits Tumor Progression In vivo by a Transforming Growth Factor-β–Regulated Mechanism
Koopman Van Aarsen, L. A., Leone, D. R., Ho, S., Dolinski, B. M., McCoon, P. E., LePage, D. J., Kelly, R., Heaney, G., Rayhorn, P., Reid, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2307 · Cited by 146 · see citing works
Exploring anti-TGF-β therapies in cancer and fibrosis
Hawinkels, L. J. A. C., & ten Dijke, P. (2011) · Growth Factors · doi:10.3109/08977194.2011.595411 · Cited by 145 · see citing works
TGF-β signaling in liver and gastrointestinal cancers
Katz, L. H., Likhter, M., Jogunoori, W. S., Belkin, M. D., Ohshiro, K., & Mishra, L. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.033 · Cited by 145 · see citing works
Fibroblast-specific Expression of a Kinase-deficient Type II Transforming Growth Factor β (TGFβ) Receptor Leads to Paradoxical Activation of TGFβ Signaling Pathways with Fibrosis in Transgenic Mice
Denton, C. P., Zheng, B., Evans, L. A., Shiwen, X., Ong, V. H., Fisher, I. B., Lazaridis, K., Abraham, D., Black, C. M., & Crombrugghe, B. D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300636200 · Cited by 141 · see citing works
Targeting Endogenous Transforming Growth Factor β Receptor Signaling in SMAD4-Deficient Human Pancreatic Carcinoma Cells Inhibits Their Invasive Phenotype
Subramanian, G., Schwarz, R. E., Higgins, L., McEnroe, G., Chakravarty, S., Dugar, S., & Reiss, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0018 · Cited by 138 · see citing works
The role of Fas ligand and transforming growth factor β in tumor progression
Kim, R., Emi, M., Tanabe, K., Uchida, Y., & Toge, T. (2004) · Cancer · doi:10.1002/cncr.20270 · Cited by 137 · see citing works
Transforming Growth Factor-Beta in Osteolytic Breast Cancer Bone Metastases
Guise, T. A., & Chirgwin, J. M. (2003) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000093055.96273.69 · Cited by 134 · see citing works
Abrogation of TGF-β signaling enhances chemokine production and correlates with prognosis in human breast cancer
Bierie, B., Chung, C. H., Parker, J. S., Stover, D. G., Cheng, N., Chytil, A. M., Aakre, M. E., Shyr, Y., & Moses, H. L. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37480 · Cited by 134 · see citing works
Expression profiling of genes regulated by TGF-beta: Differential regulation in normal and tumour cells
Ranganathan, P., Agrawal, A., Bhushan, R., Chavalmane, A. K., Kalathur, R. K. R., Takahashi, T., & Kondaiah, P. (2007) · BMC Genomics · doi:10.1186/1471-2164-8-98 · Cited by 129 · see citing works
Genetics of hepatocellular carcinoma
Teufel, A. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i16.2271 · Cited by 126 · see citing works
Transforming growth factor-β signaling: emerging stem cell target in metastatic breast cancer?
Tan, A. R., Alexe, G., & Reiß, M. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0184-1 · Cited by 124 · see citing works
TGF-β antagonists: Why suppress a tumor suppressor?
Akhurst, R. J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15970 · Cited by 120 · see citing works
Soluble cadherins as cancer biomarkers
Wever, O. D., Derycke, L., Hendrix, A., Meerleer, G. D., Godeau, F., Depypere, H. T., & Bracke, M. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9104-8 · Cited by 119 · see citing works
Mouse Mammary Tumor Virus c-rel Transgenic Mice Develop Mammary Tumors
Romieu, R., Kim, D. W., Shin, S. M., Demicco, E. G., Landesman‐Bollag, E., Seldin, D. C., Cardiff, R. D., & Sonenshein, G. E. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.16.5738-5754.2003 · Cited by 119 · see citing works
A Thrombospondin-1 Antagonist of Transforming Growth Factor-β Activation Blocks Cardiomyopathy in Rats with Diabetes and Elevated Angiotensin II
Belmadani, S., Bernal, J., Wei, C., Pallero, M. A., Dell’Italia, L. J., Murphy-Ullrich, J. E., & Berecek, K. H. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070056 · Cited by 117 · see citing works
EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis
Son, J. Y., Park, S.-Y., Kim, S., Lee, S. J., Park, S.-A., Kim, M.-J., Kim, S. W., Kim, D., Nam, J., & Sheen, Y. Y. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0903 · Cited by 115 · see citing works
Functions and regulation of transforming growth factor-beta (TGF-β) in the prostate
Danielpour, D. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2004.12.027 · Cited by 115 · see citing works
A Novel Small-Molecule Inhibitor of Transforming Growth Factor β Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection
Suzuki, E., Kim, S., Cheung, H.-K., Corbley, M. J., Zhang, X., Sun, L., Shan, F., Singh, J., Lee, W.-C., Albelda, S. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2389 · Cited by 113 · see citing works

TGF-β antagonists: Why suppress a tumor suppressor?
Akhurst, R. J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215970 · Cited by 107 · see citing works
The Outcome of TGFβ Antagonism in Metastatic Breast Cancer Models In Vivo Reflects a Complex Balance between Tumor-Suppressive and Proprogression Activities of TGFβ
Yang, Y., Yang, H. H., Tang, B., Wu, A. M. L., Flanders, K. C., Moshkovich, N., Weinberg, D. S., Welsh, M. A., Weng, J., Ochoa, H. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2370 · Cited by 29 · see citing works
Self-citation
Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases
Muraoka, R. S., Dumont, N., Ritter, C. A., Dugger, T. C., Brantley, D. M., Chen, J., Easterly, E., Roebuck, L. R., Ryan, S. T., Gotwals, P. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15234 · Cited by 485 · see citing works
Targeting the Transforming Growth Factor-β pathway inhibits human basal-like breast cancer metastasis
Ganapathy, V., Ge, R., Grazioli, A., Xie, W. Q., Banach-Petrosky, W. A., Kang, Y., Lonning, S. M., McPherson, J., Yingling, J. M., Biswas, S., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-122 · Cited by 168 · see citing works
Abstract 1549: Undesirable metastasis-stimulating effects of anti-TGF-β therapy in breast cancer models involve interference with tumor cell-autonomous tumor suppressive activity
Yang, Y., Yang, H. H., Tang, B., Wu, A. M. L., Moshkovich, N., Lee, M. Y., & Wakefield, L. M. (2019) · Immunology · doi:10.1158/1538-7445.sabcs18-1549
Self-citation

Authors: Yang, Y.-A., Dukhanina, O., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z.-Y., Green, J., Anver, M. R., Merlino, G., & Wakefield, L. M.
Affiliations: National Institutes of Health (US)
Frederick National Laboratory for Cancer Research (US)
Corresponding author: Wakefield, Lalage M.
ORCID: Mamura, Mizuko
Letterio, John J.
Green, Jeffrey
Anver, Miriam R.
Merlino, Glenn
Wakefield, Lalage M.
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 2002-06-15
Volume: 109
Issue: 12
Pages: 1607-1615
ISSN: 0021-9738 (ISSN-L)
DOI: 10.1172/jci200215333
PMC: PMC151015
OpenAlex: W2118916648
Cited by: 404
References: 50
Citations by year: 2026: 1 · 2025: 4 · 2024: 1 · 2023: 4 · 2022: 3 · 2021: 8 · 2020: 9 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 8 · 2015: 9 · 2014: 17 · 2013: 19 · 2012: 30
FWCI: 12.90
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Investigation (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: U.S. Department of Health and Human Services
National Institutes of Health (n01co12400-79-0-22, NO1-CO12400)
National Cancer Institute (N01CO12400, N01-CO-012400, NO1‐CO‐12400)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords: TGF-beta antagonists, Fc fusion protein, metastasis prevention, melanoma metastasis, MMTV-neu transgenic mice, breast cancer, transgenic mice
MeSH terms: Receptor, Transforming Growth Factor-beta Type II, Animals, Female, Genetic Vectors, Humans, Immunoglobulin G, Immunoglobulin Fc Fragments, Liver Neoplasms, Mammary Tumor Virus, Mouse, Melanoma, Experimental, Mice, Transgenic, Neoplasm Metastasis, Recombinant Fusion Proteins, Solubility, Tumor Cells, Cultured, Mammary Neoplasms, Animal, Transforming Growth Factor beta, Protein Serine-Threonine Kinases, Receptors, Transforming Growth Factor beta, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks